基于DXA三维建模评估骨质疏松药物治疗对股骨皮质骨与松质骨的影响
本研究回顾性分析155例按治疗分组的患者(未治疗、阿仑膦酸钠、地舒单抗、特立帕肽),采用基于双能X线吸收测定法(DXA)的三维建模评估股骨近端皮质骨与松质骨变化。治疗24个月后,地舒单抗组松质骨体积骨密度(vBMD)增加7.3%、皮质骨表面骨密度(sBMD)增加3.6%,特立帕肽组松质骨vBMD增加5.9%;结果与文献中计算机断层扫描所获一致。
要点
- 地舒单抗组24个月松质骨vBMD增加7.3%、皮质骨sBMD增加3.6%、皮质厚度增加1.8%。
- 特立帕肽组松质骨vBMD显著增加5.9%,皮质骨vBMD下降1.1%(非显著)。
- 基于DXA的三维建模技术可作为标准DXA检查的补充,用于监测治疗对松质骨和皮质骨间室的影响。
核心结论
- 这项头对头研究结果与文献中使用计算机断层扫描获得的结果一致。
- 基于DXA的建模技术可补充标准DXA检查,以监测治疗对松质骨和皮质骨间室的影响。
研究设计与样本
- 回顾性分析155例患者,按治疗分为未治疗组(NAIVE)、阿仑膦酸钠组(AL)、地舒单抗组(DMAB)和特立帕肽组(TPTD)。
- 在基线和治疗后进行DXA扫描,测量脊柱和股骨的面积骨密度。
- 使用软件算法(3D-SHAPER)从髋部DXA扫描导出三维模型,计算松质骨和皮质骨体积骨密度(vBMD)、皮质厚度(Cth)和皮质骨表面骨密度(cortical sBMD)。
- 变化从基线归一化至24个月,以百分比评估。
主要发现
- 未治疗组24个月后松质骨vBMD、皮质骨sBMD、Cth和皮质骨vBMD分别变化-2.3%、-0.8%、-0.3%和-0.5%,均无显著差异。
- 阿仑膦酸钠组松质骨vBMD增加3.8%、皮质骨vBMD增加1.4%、皮质骨sBMD增加1.5%,均显著。
- 地舒单抗组松质骨vBMD增加7.3%、皮质骨vBMD增加2.0%、皮质骨sBMD增加3.6%,均显著;Cth增加1.8%。
关键数值与推荐
- 未治疗组24个月:松质骨vBMD -2.3%、皮质骨sBMD -0.8%、Cth -0.3%、皮质骨vBMD -0.5%,均无显著差异。
- 阿仑膦酸钠组24个月:松质骨vBMD +3.8%、皮质骨vBMD +1.4%、皮质骨sBMD +1.5%,均显著。
- 地舒单抗组24个月:松质骨vBMD +7.3%、皮质骨vBMD +2.0%、皮质骨sBMD +3.6%,均显著;Cth +1.8%。
临床怎么用
- 作者认为,基于DXA的建模技术可补充标准DXA检查,以监测治疗对松质骨和皮质骨间室的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Effects of osteoporosis drugs on proximal femur cortical and trabecular bone were studied using dual-energy x-ray absorptiometry (DXA)-based 3D modeling method. Changes observed in this head-to-head study were consistent with those obtained using computed tomography in the literature. INTRODUCTION: The aim of the present study was to assess the effects of osteoporosis drugs on cortical and trabecular bone at the proximal femur using DXA-based 3D modeling. METHODS: We retrospectively analyzed 155 patients stratified by treatments: naive of treatment (NAIVE), alendronate (AL), denosumab (DMAB), and teriparatide (TPTD). DXA scans were performed at baseline and after treatment, and areal bone mineral density at spine and femur were measured. A software algorithm (3D-SHAPER) was used to derive 3D models from hip DXA scans and compute: trabecular and cortical volumetric BMD (vBMD), cortical thickness (Cth), and cortical surface BMD (cortical sBMD). Changes from baseline were normalized at 24 months and evaluated in terms or percentage. RESULTS: After 24 months, a non-significant decrease was observed for trabecular vBMD, Cortical sBMD, Cth, and cortical vBMD (- 2.3, - 0.8, - 0.3, and - 0.5%) in the NAIVE group. Under AL and DMAB, significant increases were observed in trabecular vBMD (3.8 and 7.3%), cortical vBMD (1.4 and 2.0%), and cortical sBMD (1.5 and 3.6%). An increase in Cth was observed in patients under DMAB (1.8%). Under TPTD, a significant increase in Trabecular vBMD was observed (5.9%) associated with a non-significant increase of Cth (+ 1%) concomitant with a decrease in cortical vBMD (- 1.1%). CONCLUSION: Results obtained in this head-to-head study are consistent with those obtained using computed tomography in the literature. DXA-based modeling techniques could complement standard DXA examination to monitor treatment effects on trabecular and cortical compartments.
引用
- Winzenrieth R, Humbert L, Di Gregorio S, et al. Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling. Osteoporos Int. 2018. PMID: 29974136. doi:10.1007/s00198-018-4624-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。